European Society of Gastrointestinal Endoscopy

Endoscopy and antiplatelet agents: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Authors: C. Boustière, A. Veitch, G. Vanbiervliet, P. Bulois, P. Deprez, A. Laquiere, R. Laugier, G. Lesur, P. Mosler, B. Nalet, B. Napoleon, B. Rembacken, N. Ajzenberg, J. P. Collet, T. Baron, J.-M. Dumonceau

Abstract

With the increasing use of antiplatelet agents (APA), their management during the periendoscopic period has become a more common and more difficult problem. The increase in use is due to the availability of new drugs and the widespread use of drug-eluting coronary stents. Acute coronary syndromes can occur when APA therapy is withheld for noncardiovascular interventions. Guidelines about APA management during the periendoscopic period are traditionally based on assessments of the procedure-related risk of bleeding and the risk of thrombosis if APA are stopped. New data allow better assessment of these risks, of the necessary duration of APA discontinuation before endoscopy, of the use of alternative procedures (mostly for endoscopic retrograde cholangiopancreatography [ERCP]), and of endoscopic methods that can be used to prevent bleeding (following colonic polypectomy). This guideline makes graded, evidence-based, recommendations for the management of APA for all currently performed endoscopic procedures. A short summary and two Tables are included for quick reference.

Endoscopy and antiplatelet agents: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Download full guideline

DOI http://dx.doi.org/10.1055/s-0030-1256317
Endoscopy 2011; 43:445–458
© Georg Thieme Verlag KG Stuttgart· New York